Approaches to the management of systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 9, Issue 5, 1997, Pages 410-420

  Strand, Vibeke ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CLADRIBINE; COMPLEMENT; CYTOKINE; DEOXYADENOSINE DERIVATIVE; DNA ANTIBODY; IMMUNOMODULATING AGENT; LEFLUNOMIDE; LEUKOTRIENE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PRASTERONE; PROSTAGLANDIN; TAMOXIFEN;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL INTERACTION; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; DISEASE COURSE; GENE THERAPY; HUMAN; INTERNATIONAL COOPERATION; METHODOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; COMPLEMENT INACTIVATOR PROTEINS; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; STEM CELL TRANSPLANTATION;

EID: 0030772676     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199709000-00006     Document Type: Review

References (80)

1. Mohan C, Shi Y, Ion D, et al.: Long term benefits of a brief anti-gp39 therapy in murine lupus. Arthritis Rheum 1994, 37:S369.
2. Reiser H, Stadecker MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996, 335:1369-1375. A detailed overview of the role of costimulatory B7 molecules.
3. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993, 11:191-212.
4. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
5. Daikh ID, Palmer B, Finck B, et al.: CTLA4Ig Inhibits cytokine production by CD4 T cells in NZB/NZW lupus-prone mice. Arthritis Rheum 1996, 39:S106.
6. Abrams J: Presentation, Innovative Therapies in Autoimmune Diseases, April 4, 1997, Washington, DC.
7. Nakajima, Azuma M, Kodera S: Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol 1995, 13:179-200.
8. Daikh D, Wofsy D: The immune response to anti-B7 antibodies is dose dependent: low doses elicit a potent response while high doses block the immune response. Arthritis Rheum 1996, 39:S106. Use of antibodies to both B7-1 and B7-2 is necessary to downregulate immune responses.
9. Jacob L, Lety MA, Luvard D, Bach J-F: Binding of a monoclonal anti DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis. J Clin Invest 1985, 75:315-317.
10. Fillit H, Shibata S, Sasaki T: Autoantibodies to the protein core of vascular basement membrane heparin sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity 1993, 14:243-249.
11. Strand V, Lee M: Intravenous immunoglobulin (IVIg) in the treatment of autoimmune diseases. In Novel Therapeutic Agents for the Treatment of Autoimmune Diseases. Edited by Strand V, Scott DL, Simon LS. New York: Dekker; 1997:235-256. Overview of the use of IVIg in autoimmune disease indications and its postulated mechanisms of action.
12. Shroider JO, Zeuner RA, Euler HH, Loffler H: High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996, 23:71-75.
13. Williams RC, Malone CC, Silvestris F: Eluates from anti-DNA-Id affinity columns containing F4+, 31+, 8.12+ and 16/6+ human IgG myelomas produce specific anti-id antibodies from intravenous gamma globulin. Arthritis Rheum 1996, 39:S307. Evidence for anti-idiotype-anti-DNA antibodies in IVIg preparations.
14. Abdou NI, Suenega R: Immunoregulation in SLE by idiotypic network: possible future therapeutic implications. In Monoclonal Antibodies, Cytokines and Arthritis, Edited by Kresina T. New York: Dekker; 1991:465-473.
15. Hahn BH, Ebling FM: Idiotypic restriction in murine lupus: high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice. J Immunol 1987, 138:2110-2118.
16. Weisbart RH, Noritake DT, Wong AL: A conserved anti DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J Immunol 1990, 144:2653-2658.
17. Lee ML, Spertini F, Leimgruber A: Updated phase 1 clinical results with an idiotypic vaccine (3E 10) for systemic lupus erythematisus (SLE). Arthritis Rheum 1995, 8:S303.
18. Spertini F, Leimgruber A, Morel B: Idiotypic vaccination in lupus nephritis with a murine anti-dsDNA antibody. Submitted for publication.
19. Jones DS, Barstad PA, Feild MJ: Immunospecific reduction of anti-oligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a theraputic candidate for the treatment of lupus nephritis. J Med Chem 1995, 38:2138-2144.
20. Weisman MH, Blustein HG, Berner CM: Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997, 24:314-318. Immediate reduction in anti-dsDNA antibody titers after treatment due to immunoadsorption.
21. Hepburn B, Furie R, Cash J: Reduction of anti-DS DNA antibodies using LJP 394 in patients with lupus. Arthritis Rheum 1996, 39:S307. Immediate and long-term effects on anti-dsDNA antibodies by treatment with LJP 394.
22. Hepburn B: Presentation, Innovative Therapies in Autoimmune Diseases, April 4, 1997, Washington, DC.
23. Gaynor B, Putterman C, Valadon P: Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A 1997, 94:1955-1960. Administration of D amino acid peptides crossreactive with anti-dsDNA antibodies inhibited antibody deposition in the kidneys of SCID mice.
24. Klinman D, Elias K, Shak S, Verthely D: DNAse treatment of DNA-anti-DNA immune complexes in SLE. Arthritis Rheum 1996, 39:S307. Daily DNAse treatment for 3 weeks resulted in reduced numbers of splenic B cells secreting IgG anti-dsDNA antibodies, presumably by dissolving immune complexes that persistently activate atuoreactive B cells.
25. Hale VG, Braum JV, Richardson L: Recombinant human DNAse (rhDNAse) for SLE nephritis: characterization of safety, tolerance and disposition following systemic administration. Arthritis Rheum 1996, 39:S254. In healthy women with normal renal function subcutaneous dosing of recombinant human DNAse resulted in urinary concentrations estimated to be in the active range for solubilizing anti-dsDNA antibody immune complexes.
26. Matis LA, Rollins SA: Complement-specific antibodies: designing novel anti-inflammatories. Nat Med 1995, 1:839-842.
27. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Sci U S A 1996, 93:8563-8568. Treatment of NZB/W mice after dsDNA antibodies became evident (approximately 4 months) delayed onset of proteinuria and prolonged survival.
28. Wang Y, Hu O, Kristan J: Subcutaneous administration of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses. Arthritis Rheum 1996, 39:S245. A fully humanized monoclonal antibody to complement 5 was effective in inhibiting complement activation in C5-deficient mice reconstituted with purified human C5.
29. Matis L: Presentation, Innovative Therapies in Autoimmune Diseases, April 4, 1997, Washington, DC.
30. Llorenta L, Richard-Patin Y, Ruiz-Soto R: Immune dysregulation in systemic lupus erythematosus and in families of patients with lupus due to high level production of IL-10. Arthritis Rheum 1996, 39:S250.
31. Park YB, Lee J, Lee CH: Elevated IL-10 level correlated with disease activity in systemic lupus erythematosus (SLE). Arthritis Rheum 1996, 39:S250.
32. Georgescu L, Vakkalanka RK, Elkon K: Interleukin-10 induces accelerated in vitro apoptosis in systemic lupus erythematosus (SLE). Arthritis Rheum 1996, 39:S145.
33. Horowitz D, Gray JD, Ohtsuka K: Regulation of TGFβ1 produced by human blood mononuclear cells by mitogens and cytokines. Arthritis Rheum 1996, 39:S251.
34. Grondal G, Gunnarsson I, Ronneld J: Cytokine production and disease activity in systemic lupus erythematosus. Arthritis Rheum 1996, 39:S251.
35. Ishida H, Muchamuel T, Sakaguchi S: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
36. Llorente L, Zou W, Lewy Y: Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
37. Alcocer-Varela J, Llorente L, Alarcon-Segovia D: Immunoregulatory circuits and potential treatment of connective tissue diseases. Int Arch Allergy Immunol 1996, 111:348-354. Overview of immunoregulatory circuitry, alterations in SLE and rheumatoid arthritis, and potential benefits of treatment with anti-interleukin-10 and interleukin-10, respectively.
38. Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA: Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995, 4:286-292.
39. Marmont AM, Tyndall A, Gratwohl A, Vischer T: Hematopoietic precursor cell transplants for autoimmune diseases. Lancet 1995, 345:978.
40. Role of Hematopoietic Stem Cell Transplantation for Autoimmune Diseases, Fred Hutchinson Cancer Research Center, Seattle, USA, October 27, 1995. J Rheumatol 1997, 24(suppl 48).
41. Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154.
42. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E: Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996, 5:237-241. One of three controlled trials, the second to show benefit for antimalarial therapy, allowing taper of prednisone doses.
43. Bansal VK, Beto JA: Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997, 29:193-199. Meta-analysis of SLE nephritis trials: 440 patients in 19 trials, eight from the NIH, four from the Mayo clinic, showing the superiority of any combination of immunosuppressives with prednisone versus prednisone alone and showing no difference between immunosuppressives or between oral versus intravenous administration.
44. Gourley MF, Austin HA, Scott D: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996, 125:549-557. NIH experience in 82 patients showed superiority of cyclophosphamide (or combination) versus prednisone alone.
45. Segal R, Dayan M, Zinger H: Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE): clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995, 101:66-72.
46. Wise CM, Vuyyuru S, Roberts WN: Methotrexate in nonrenal lupus and undifferentiated connnective tissue disease: a review of 36 patients. J Rheumatol 1996, 23:1005-1010.
47. Radhakrishnan J, Kunis CL, D'Agati V, Appel GB: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994, 42:147-154. Results of open-label treatment of SLE membranous nephropathy with cyclosporine.
48. Caccavo D, Laganá B, Mitterhofer AP, et al.: Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997, 40:27-35. Of 27 patients treated for at least 24 months with cyclosporine, nephrotoxicity was observed in four.
49. Manger K, Kalden JR, Manger B: Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996, 35:669-675. Positive clinical experience in 16 patients, although hypertension and deterioration of renal function were observed in three.
50. Moreira AL, Sampaio EP, Zmuidzinas A: Thalidomide exerts its inhibitory action on TNFα by enhancing mRNA degradation. J Exp Med 1993, 177:1675.
51. Stevens RJ, Andujar C, Edwards C: Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. Arthritis Rheum 1996, 39:S253. Open-label treatment with thalidomide of 16 patients with SLE rashes refractory to commonly used agents.
52. Sato EI, Assis LSS, Furtado A: Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE). Arthritis Rheum 1996, 39:S253. Open-label treatment with thalidomide of 18 patients with cutaneous manifestations of SLE.
53. Scott D, Balow J, Austin III H: A pilot study of cladribine (2′-chlorodeoxyadenosine) in lupus nephritis. Arthritis Rheum 1995, 38:S304.
54. Holocombe RF, Elder C, Wolf RE: 2-Chlorodeoxyadenosine (2-CdA) in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Arthritis Rheum 1995, 38:S304.
55. Davis JC, Klippel J, Boumpas D: 2′ Chlorodeoxyadenosine (2-CdA) treatment in lupus nephritis. Arthritis Rheum 1996, 9:S254. NIH open-label series of 12 patients with SLE nephritis who received treatment with 2′-chlorodeoxyadenosine.
56. Hearth-Holmes M, Holcolmbe RF, Elder C: 2′-Chlorodeoxyadenosine (2-CdA) in patients with lupus nephritis. Arthritis Rheum 1996, 9:S254. LSU open-label experience treating four patients with SLE nephritis with 2-chlorodeoxyadenosine.
57. Mladenovic V, Domljan Z, Rozman B: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995, 38:1595-1603.
58. Leflunomide Investigators' Brochure. Wiesbaden, Germany: Hoechst Marion Roussel; 1996.
59. Mozes E, Segal R, Sthoeger Z: Modulation of experimental systemic lupus arythematosus. Isr J Med Sci 1996, 32:19-21. A review of recent data on experimental agents in murine models of SLE (tamoxifen, methotrexate, and methimazole).
60. Lahita RG, Cheng CY, Monder C, Bardin CW: Experience with 19 nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19 nor testosterone in men and lack of improvement in women. J Rheumatol 1992, 19:547-555.
61. Van Vollenhoven RF, McDevitt HO: Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone. Arthritis Rheum 1992, 35:S207.
62. Van Vollenhoven RF, Engleman EG, McGuire JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1305-1309.
63. van Vollenhoven RF, Engleman EG, McGuire JL: Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995, 38:1826-1831.
64. Schwartz K: Presentation, Innovative Therapies in Autoimmune Diseases, April 4, 1997, Washington, DC.
65. Apelgren LD, Bailey DL, Fouts RL: The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice. Cell Immunol 1996, 173:55-63. Daily treatment of female MRL/lpr mice with a selective estrogen inhibitor modulator for 7 months increased survival without alteration in autoantibody formation.
66. Walker SE, Allen SH, Hovvman RW, McMurray RW: Review: prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 1995, 4:3-9.
67. McMurray R, Keisler D, Kanuckel K, Izui S, Walker WE: Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1992, 147:3780-3787.
68. Blank M, Krause I, Buskila D: Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995, 162:114-122.
69. Alvarez-Nemegyei J, Covarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Jara LJ: Bromocriptine in systemic lupus erythematosus: a double blind, randomized placebo controlled study. Arthritis Rheum 1996, 39:S253.
70. Clark WF, Parbtani A: Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis 1994, 23:644-647.
71. Ilowite NT, Copperman N, Leicht T: Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 1995, 22:1347-1351.
72. Pierucci A, Simonetti BM, Pecci G: Improvement of renal function with selective thromboxane antagonist in lupus nephritis. N Engl J Med 1989, 320:421-425.
73. 2 synthetase inhibitor.
74. Yoshida T, Ichikawa Y, Tojo T, Homma M: Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. Lupus 1996, 5:129-138. Urinary levels of prostanoids and the effect of 3 days' treatment with DP-1904 were studied in 31 patients with SLE nephritis and 10 without nephritis. Eight patients with SLE nephritis received 4 days' treatment with DP-1904.
75. Yoshikawa Y, Mizutani H, Shimuizu M: Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Cutis 1996, 58:393-396. Single case report of improvement in a male patient with cutaneous vasculitis and neuropathy with antiphospholipid antibodies.
76. Weinblatt ME, Kremer JM, Coblyn JS, et al.: Zileuton, a 5′ lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 1992, 19:1537-1541.
77. Hackshaw KV, Shi Y, Brandwein SR, Jones K, Westcott JY: A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. J Rheumatol 1995, 22:462-468.
78. Weinberg JB, Granger DL, Pisetsky DS, et al.: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-1-arginine. J Exp Med 1994, 179:651-660.
79. Goel A, Belmont HM, Giorno R, et al.: Inducible nitric oxide synthase is upregulated in vascular endothelium and keratinocytes of nonlesional skin in patients with active SLE. Arthritis Rheum 1996, 39:S291.
80. Hortelano S, Diaz-Guerra MJM, Gonzales-Garcia A, et al.: Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr mice. J Immunol 1997, 158:1402-1408. Roquinimex (linomide) treatment prevents nephritis in MRL/Mp-lpr/lpr mice, presumably by inhibition of nitric oxide synthesis and decreased tumor necrosis factor-α production.